IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent A	Application of			
HORVAIS ET	ΓAL.	Atty. Ref.:	960-49	
Serial No.	10/583,948	Group:	1637	
Filed: O	ctober 20, 2006	Examiner:	Bertagna	
For: SOLII	D SUPPORT FOR NUCLEIC ACID D	DETECTION		
	* * * * * *	* * * *	*	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
Sir:	INFORMATION DISCLOSU	RE STATEME	<u>NT</u>	
☑ 1.	PTO-1449 Pursuant to 37 CFR 1. [within 3 months of filing or prior to		on on the merits	
2.(a)	Statement Pursuant to 37 CFR 1. [before Final Office Action or Allow Statement or Rule 17(p) fee)]		Rule 97(e) N/C	
2 .(b)	Fee Payment Pursuant to 37 CFF [before Final Office Action or Allow Statement or Rule 17(p) fee)]		Rule 97(e) \$180.00	
3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowar Statement and Rule 17(p) fee), but			

Information Disclosure Statement December 9, 2008

The following are submitted in the above-identified application in compliance with 37 C.F.R. $\S\S$ 1.97 and 1.98:

	4.	ider eac	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.			
This p	paper	is sub	emitted in accordance with:			
\boxtimes	5.	37 (CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]			
	6.	37 (and	CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]			
		a)	The required Statement made in item 8 below; or			
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.			
	7.		CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) ement and Rule 17(p) fee), but before final fee payment]; and			
		a)	The fee (\$180.00) required by 37 CFR $\S1.17(p)$ is submitted herewith; and			
		b)	The required Statement is stated in item 8 below.			
	8.	Stat	ement under 37 CFR 1.97(e)			
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or			
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			

Information Disclosure Statement December 9, 2008

 Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100